Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 2
1952 1
1970 1
1972 1
1977 1
1978 1
1985 2
1991 2
1993 1
1994 2
1995 1
1996 2
2004 1
2005 1
2006 1
2007 3
2008 4
2009 4
2010 1
2012 2
2013 2
2014 2
2015 3
2016 4
2017 6
2018 10
2019 18
2020 34
2021 48
2022 35
2023 38
2024 53
2025 41

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

297 results

Results by year

Filters applied: . Clear all
Page 1
Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, Howard TP, Takeda DY, Ly SH, Kim E, Gannon HS, Hurhula B, Sharpe T, Goodale A, Fritchman B, Steelman S, Vazquez F, Tsherniak A, Aguirre AJ, Doench JG, Piccioni F, Roberts CWM, Meyerson M, Getz G, Johannessen CM, Root DE, Hahn WC. Giacomelli AO, et al. Nat Genet. 2018 Oct;50(10):1381-1387. doi: 10.1038/s41588-018-0204-y. Epub 2018 Sep 17. Nat Genet. 2018. PMID: 30224644 Free PMC article.
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.
Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkowic K, Piccioni F, Root DE, Rücker FG, Flamand Y, Neuberg D, Lindsley RC, Jänne PA, Hahn WC, Jacks T, Döhner H, Armstrong SA, Ebert BL. Boettcher S, et al. Among authors: giacomelli ao. Science. 2019 Aug 9;365(6453):599-604. doi: 10.1126/science.aax3649. Science. 2019. PMID: 31395785 Free PMC article.
RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4.
Weinstein HNW, Hu K, Fish L, Chen YA, Allegakoen P, Pham JH, Hui KSF, Chang CH, Tutar M, Benitez-Rivera L, Baco MB, Song H, Giacomelli AO, Vazquez F, Ghandi M, Goodarzi H, Huang FW. Weinstein HNW, et al. Among authors: giacomelli ao. Cell Rep. 2024 Aug 27;43(8):114622. doi: 10.1016/j.celrep.2024.114622. Epub 2024 Aug 14. Cell Rep. 2024. PMID: 39146182 Free PMC article.
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ, Dilly J, Liu S, Kim E, Bian Y, Dharmaiah S, Tran TH, Kapner KS, Ly SH, Yang X, Rabara D, Waybright TJ, Giacomelli AO, Hong AL, Misek S, Wang B, Ravi A, Doench JG, Beroukhim R, Lemke CT, Haigis KM, Esposito D, Root DE, Nissley DV, Stephen AG, McCormick F, Simanshu DK, Hahn WC, Aguirre AJ. Kwon JJ, et al. Among authors: giacomelli ao. bioRxiv [Preprint]. 2024 Oct 25:2024.10.22.618529. doi: 10.1101/2024.10.22.618529. bioRxiv. 2024. PMID: 39484452 Free PMC article. Preprint.
Update on Mpox: a brief narrative review.
Antinori S, Casalini G, Giacomelli A, Rodriguez-Morales AJ. Antinori S, et al. Among authors: giacomelli a. Infez Med. 2023 Sep 1;31(3):269-276. doi: 10.53854/liim-3103-1. eCollection 2023. Infez Med. 2023. PMID: 37701385 Free PMC article. Review.
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation.
Mussini C, Giacomelli A, Quiros-Roldan E, Mazzotta V, Di Biagio A, De Vito A, Costantini A, D'Ettorre G, Giacometti A, Vergori A, Tavelli A, Malagnino V, Castagna A, Chester J, Antinori A, d'Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Cohort Study for the Icona Foundation Study Group. Mussini C, et al. Among authors: giacomelli a. EClinicalMedicine. 2025 Jul 24;86:103368. doi: 10.1016/j.eclinm.2025.103368. eCollection 2025 Aug. EClinicalMedicine. 2025. PMID: 40740293 Free PMC article.
RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4.
Weinstein HNW, Hu K, Fish L, Chen YA, Allegakoen P, Hui KSF, Pham JH, Baco MB, Song H, Giacomelli AO, Vazquez F, Ghandi M, Goodarzi H, Huang FW. Weinstein HNW, et al. Among authors: giacomelli ao. bioRxiv [Preprint]. 2023 Dec 10:2023.12.10.570873. doi: 10.1101/2023.12.10.570873. bioRxiv. 2023. Update in: Cell Rep. 2024 Aug 27;43(8):114622. doi: 10.1016/j.celrep.2024.114622. PMID: 38106152 Free PMC article. Updated. Preprint.
297 results